Skip to content
2000
Volume 14, Issue 3
  • ISSN: 2211-5501
  • E-ISSN: 2211-551X

Abstract

The flavivirus family belongs to antigenically closely related viruses that have been a public health concern across the globe. It is well observed that infection by specific flavivirus serotypes can confer lifelong immunity. However, there is an alarming situation of cross-reactivity between antibodies of other flaviviruses or other serotypes without cross-protection. Cross-reaction without cross-neutralising from heterologous flavivirus infection leads to antibody-dependent enhancement (ADE) of disease severity. Antibody-dependent enhancement occurs when sub-neutralising or non-neutralising antibodies generated during a primary flavivirus infection or after vaccination facilitate enhanced viral entry and replication in the host cells. The underlying mechanisms of ADE involve interactions between the antigen-antibody complexes towards the Fc receptors and the complement system. This review provides an overview of the current knowledge on ADE in flavivirus pathogenesis, emphasising the importance of understanding its implications for immune responses, therapeutics and vaccine development.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cbiot/10.2174/0122115501364702250707105742
2025-07-11
2026-02-24

  • From This Site

    /content/journals/cbiot/10.2174/0122115501364702250707105742
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LoganR.A.E. QuekS. MuthoniJ.N. von EickenA. BrettellL.E. AndersonE.R. VillenaM.E.N. HegdeS. PattersonG.T. HeinzE. HughesG.L. PattersonE.I. Vertical and horizontal transmission of cell fusing agent virus in Aedes aegypti.Appl. Environ. Microbiol.20228818e01062-2210.1128/aem.01062‑2236036577
     [Google Scholar]
  2. Wilder-SmithA. GublerD.J. WeaverS.C. MonathT.P. HeymannD.L. ScottT.W. Epidemic arboviral diseases: Priorities for research and public health.Lancet Infect. Dis.2017173e101e10610.1016/S1473‑3099(16)30518‑728011234
     [Google Scholar]
  3. MansfieldK.L. Hernández-TrianaL.M. BanyardA.C. FooksA.R. JohnsonN. Japanese encephalitis virus infection, diagnosis and control in domestic animals.Vet. Microbiol.2017201859210.1016/j.vetmic.2017.01.01428284628
     [Google Scholar]
  4. MaclachlanN.J. DuboviE.J. Fenner’s veterinary virology.Academic press2010
     [Google Scholar]
  5. AcklinJ.A. CattleJ.D. MossA.S. BrownJ.A. FosterG.A. KrysztofD. StramerS.L. LimJ.K. Evaluating the safety of West Nile virus immunity during congenital Zika virus infection in mice.Front. Immunol.20211268641110.3389/fimmu.2021.68641134220838
     [Google Scholar]
  6. GargH. YehR. WattsD.M. Mehmetoglu-GurbuzT. ResendesR. ParsonsB. GonzalesF. JoshiA. Enhancement of Zika virus infection by antibodies from West Nile virus seropositive individuals with no history of clinical infection.BMC Immunol.2021221510.1186/s12865‑020‑00389‑233421988
     [Google Scholar]
  7. Santos-PeralA. LuppaF. GoreschS. NikolovaE. ZauchaM. LehmannL. DahlstroemF. KarimzadehH. Thorn-SesholdJ. WinheimE. SchusterE.M. DoblerG. HoelscherM. KümmererB.M. EndresS. SchoberK. KrugA.B. PritschM. Barba-SpaethG. RothenfusserS. Prior flavivirus immunity skews the yellow fever vaccine response to cross-reactive antibodies with potential to enhance dengue virus infection.Nat. Commun.2024151169610.1038/s41467‑024‑45806‑x38402207
     [Google Scholar]
  8. KotakiT. NagaiY. YamanakaA. KonishiE. KameokaM. Japanese encephalitis DNA vaccines with epitope modification reduce the induction of cross-reactive antibodies against dengue virus and antibody-dependent enhancement of dengue virus infection.Vaccines2022109141110.3390/vaccines1009141136146489
     [Google Scholar]
  9. KubinskiM. BeichtJ. GerlachT. VolzA. SutterG. RimmelzwaanG.F. Tick-borne encephalitis virus: A quest for better vaccines against a virus on the rise.Vaccines20208345110.3390/vaccines803045132806696
     [Google Scholar]
  10. SinhaS. SinghK. Ravi KumarY.S. RoyR. PhadnisS. MeenaV. BhattacharyyaS. VermaB. Dengue virus pathogenesis and host molecular machineries.J. Biomed. Sci.20243114310.1186/s12929‑024‑01030‑938649998
     [Google Scholar]
  11. KokW.M. New developments in flavivirus drug discovery.Expert Opin. Drug Discov.201611543344510.1517/17460441.2016.116088726966889
     [Google Scholar]
  12. Dengue and severe dengue.2024Available from: https://www. who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue
  13. DuttaS.K. LangenburgT. A perspective on current flavivirus vaccine development: A brief review.Viruses202315486010.3390/v1504086037112840
     [Google Scholar]
  14. Elong NgonoA. ChenH.W. TangW.W. JooY. KingK. WeiskopfD. SidneyJ. SetteA. ShrestaS. Protective role of cross-reactive CD8 T cells against dengue virus infection.EBioMedicine20161328429310.1016/j.ebiom.2016.10.00627746192
     [Google Scholar]
  15. de A CamargoF. AdimyM. EstevaL. MétayerC. FerreiraC.P. Modeling the relationship between antibody-dependent enhancement and disease severity in secondary dengue infection.Bull. Math. Biol.20218388510.1007/s11538‑021‑00919‑y34142264
     [Google Scholar]
  16. HalsteadSB Neutralization and antibody-dependent enhancement of dengue viruses.Adv Virus Res20036042146710.1016/s0065‑3527(03)60011‑414689700
     [Google Scholar]
  17. GuoZ. JingW. LiuJ. LiuM. The global trends and regional differences in incidence of Zika virus infection and implications for Zika virus infection prevention.PLoS Negl. Trop. Dis.20221610e001081210.1371/journal.pntd.001081236269778
     [Google Scholar]
  18. BhagatR. KaurG. SethP. Molecular mechanisms of zika virus pathogenesis.Indian J. Med. Res.2021154343344510.4103/ijmr.IJMR_169_2035345069
     [Google Scholar]
  19. SirohiD. KuhnR.J. Zika virus structure, maturation, and receptors.J. Infect. Dis.2017216Suppl. 10S935S94410.1093/infdis/jix51529267925
     [Google Scholar]
  20. CoxB.D. StantonR.A. SchinaziR.F. Predicting Zika virus structural biology: Challenges and opportunities for intervention.Antivir. Chem. Chemother.2015243-411812610.1177/204020661665387327296393
     [Google Scholar]
  21. LabibB.A. ChigbuD.I. Pathogenesis and manifestations of Zika virus-associated ocular diseases.Trop. Med. Infect. Dis.20227610610.3390/tropicalmed706010635736984
     [Google Scholar]
  22. ZhaoH. FernandezE. DowdK.A. SpeerS.D. PlattD.J. GormanM.J. GoveroJ. NelsonC.A. PiersonT.C. DiamondM.S. FremontD.H. Structural basis of Zika virus-specific antibody protection.Cell201616641016102710.1016/j.cell.2016.07.02027475895
     [Google Scholar]
  23. Cruz-OliveiraC. FreireJ.M. ConceiçãoT.M. HigaL.M. CastanhoM.A.R.B. Da PoianA.T. Receptors and routes of dengue virus entry into the host cells.FEMS Microbiol. Rev.201539215517010.1093/femsre/fuu00425725010
     [Google Scholar]
  24. DaiL. SongJ. LuX. DengY.Q. MusyokiA.M. ChengH. ZhangY. YuanY. SongH. HaywoodJ. XiaoH. YanJ. ShiY. QinC.F. QiJ. GaoG.F. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody.Cell Host Microbe201619569670410.1016/j.chom.2016.04.01327158114
     [Google Scholar]
  25. TaylorA. FooS.S. BruzzoneR. Vu DinhL. KingN.J.C. MahalingamS. Fc receptors in antibody-dependent enhancement of viral infections.Immunol. Rev.2015268134036410.1111/imr.1236726497532
     [Google Scholar]
  26. AdamsC. CarbaughD.L. ShuB. NgT.S. CastilloI.N. BhowmikR. Segovia-ChumbezB. PuhlA.C. GrahamS. DiehlS.A. LazearH.M. LokS. de SilvaA.M. PremkumarL. Structure and neutralization mechanism of a human antibody targeting a complex Epitope on Zika virus.PLoS Pathog.2023191e101081410.1371/journal.ppat.101081436626401
     [Google Scholar]
  27. YenL.C. ChenH.W. HoC.L. LinC.C. LinY.L. YangQ.W. ChiuK.C. LienS.P. LinR.J. LiaoC.L. Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement.J. Biomed. Sci.20233014110.1186/s12929‑023‑00938‑y37316861
     [Google Scholar]
  28. HalsteadS.B. NimmannityaS. CohenS.N. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered.Yale J. Biol. Med.19704253113285419206
     [Google Scholar]
  29. RoyS.K. BhattacharjeeS. Dengue virus: Epidemiology, biology, and disease aetiology.Can. J. Microbiol.2021671068770210.1139/cjm‑2020‑057234171205
     [Google Scholar]
  30. AndradeP. NarvekarP. MontoyaM. MichlmayrD. BalmasedaA. ColomaJ. HarrisE. Primary and secondary dengue virus infections elicit similar memory B-Cell responses, but breadth to other serotypes and cross-reactivity to Zika virus is higher in secondary dengue.J. Infect. Dis.2020222459060010.1093/infdis/jiaa12032193549
     [Google Scholar]
  31. Acosta e.g BartenschlagerR. Paradoxical role of antibodies in dengue virus infections: Considerations for prophylactic vaccine development.Expert Rev. Vaccines201615446748210.1586/14760584.2016.112181426577689
     [Google Scholar]
  32. PiersonT.C. XuQ. NelsonS. OliphantT. NybakkenG.E. FremontD.H. DiamondM.S. The stoichiometry of antibody- mediated neutralization and enhancement of West Nile virus infection.Cell Host Microbe20071213514510.1016/j.chom.2007.03.00218005691
     [Google Scholar]
  33. LeeW.S. WheatleyA.K. KentS.J. DeKoskyB.J. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.Nat. Microbiol.20205101185119110.1038/s41564‑020‑00789‑532908214
     [Google Scholar]
  34. NarayanR. TripathiS. Intrinsic ADE: The dark side of antibody dependent enhancement during dengue infection.Front. Cell. Infect. Microbiol.20201058009610.3389/fcimb.2020.58009633123500
     [Google Scholar]
  35. ThomasS. SmattiM.K. OuhtitA. CyprianF.S. AlmaslamaniM.A. ThaniA.A. YassineH.M. Antibody-Dependent Enhancement (ADE) and the role of complement system in disease pathogenesis.Mol. Immunol.202215217218210.1016/j.molimm.2022.11.01036371813
     [Google Scholar]
  36. TranL. RadwanI. MinhL.H.N. LowS.K. HashanM.R. GomaaM.D. AbdelmongyM. AbdelazizA.I. MohamedA. TawfikG.M. MizukamiS. HirayamaK. HuyN.T. Role of cytokines produced by T helper immune-modulators in dengue pathogenesis: A systematic review and meta-analysis.Acta Trop.202121610582310.1016/j.actatropica.2021.10582333421421
     [Google Scholar]
  37. ChongH.Y. LeowC.Y. Abdul MajeedA.B. LeowC.H. Flavivirus infection—A review of immunopathogenesis, immunological response, and immunodiagnosis.Virus Res.201927419777010.1016/j.virusres.2019.19777031626874
     [Google Scholar]
  38. ChanK.R. IsmailA.A. ThergarajanG. RajuC.S. YamH.C. RishyaM. SekaranS.D. Serological cross-reactivity among common flaviviruses.Front. Cell. Infect. Microbiol.20221297539810.3389/fcimb.2022.97539836189346
     [Google Scholar]
  39. IzmirlyA.M. AlturkiS.O. AlturkiS.O. ConnorsJ. HaddadE.K. Challenges in dengue vaccines development: Pre-existing infections and cross-reactivity.Front. Immunol.202011105510.3389/fimmu.2020.0105532655548
     [Google Scholar]
  40. HalsteadSB Pathogenic exploitation of Fc activity.Antibody Fc Linking Adaptive and Innate ImmunityAcademic PressCambridge, Massachusetts201410.1016/B978‑0‑12‑394802‑1.00019‑4
     [Google Scholar]
  41. SarkerA. DhamaN. GuptaR.D. Dengue virus neutralizing antibody: A review of targets, cross-reactivity, and antibody-dependent enhancement.Front. Immunol.202314120019510.3389/fimmu.2023.120019537334355
     [Google Scholar]
  42. DejnirattisaiW. JumnainsongA. OnsirisakulN. FittonP. VasanawathanaS. LimpitikulW. PuttikhuntC. EdwardsC. DuangchindaT. SupasaS. ChawansuntatiK. Enhancing cross-reactive anti-prM dominates the human antibody response in dengue infection.Science2010328597910.1126/science.118518120448183
     [Google Scholar]
  43. GuilliamsM. BruhnsP. SaeysY. HammadH. LambrechtB.N. The function of Fcγ receptors in dendritic cells and macrophages.Nat. Rev. Immunol.20141429410810.1038/nri358224445665
     [Google Scholar]
  44. UbolS. PhukliaW. KalayanaroojS. ModhiranN. Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies.J. Infect. Dis.2010201692393510.1086/65101820158392
     [Google Scholar]
  45. ZhangX. XiaH. WangQ. CuiM. ZhangC. WangQ. LiuX. ChenK. SOCSs: Important regulators of host cell susceptibility or resistance to viral infection.Z. Naturforsch. C J. Biosci.2023789-1032733510.1515/znc‑2023‑002437233326
     [Google Scholar]
  46. GranatoM. SantarelliR. FarinaA. GonnellaR. LottiL.V. FaggioniA. CironeM. Epstein-barr virus blocks the autophagic flux and appropriates the autophagic machinery to enhance viral replication.J. Virol.20148821127151272610.1128/JVI.02199‑1425142602
     [Google Scholar]
  47. ByrneA.B. TalaricoL.B. Role of the complement system in antibody-dependent enhancement of flavivirus infections.Int. J. Infect. Dis.202110340441110.1016/j.ijid.2020.12.03933352325
     [Google Scholar]
  48. CondeJ.N. SilvaE.M. BarbosaA.S. Mohana-BorgesR. The complement system in flavivirus infections.Front. Microbiol.2017821310.3389/fmicb.2017.0021328261172
     [Google Scholar]
  49. MerleN.S. NoeR. Halbwachs-MecarelliL. Fremeaux-BacchiV. RoumeninaL.T. Complement system part II: Role in immunity.Front. Immunol.2015625710.3389/fimmu.2015.0025726074922
     [Google Scholar]
  50. DuensingTD WatsonSR Complement-dependent cytotoxicity assay.Cold Spring Harb Protoc20182018210.1101/pdb.prot09379929438057
     [Google Scholar]
  51. WangG. de JongR.N. van den BremerE.T.J. BeurskensF.J. LabrijnA.F. UgurlarD. GrosP. SchuurmanJ. ParrenP.W.H.I. HeckA.J.R. Molecular basis of assembly and activation of complement component C1 in complex with immunoglobulin G1 and antigen.Mol. Cell201663113514510.1016/j.molcel.2016.05.01627320199
     [Google Scholar]
  52. von KietzellK. PozzutoT. HeilbronnR. GrösslT. FechnerH. WegerS. Antibody-mediated enhancement of parvovirus B19 uptake into endothelial cells mediated by a receptor for complement factor C1q.J. Virol.201488148102811510.1128/JVI.00649‑1424807719
     [Google Scholar]
  53. IshikawaT. YamanakaA. KonishiE. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available.Vaccine201432121326133710.1016/j.vaccine.2014.01.04024486372
     [Google Scholar]
  54. LowJ.G.H. OoiE.E. VasudevanS.G. Current status of dengue therapeutics research and development.J. Infect. Dis.2017215Suppl. 2S96S10210.1093/infdis/jiw42328403438
     [Google Scholar]
  55. MorsyS. HashanM.R. HieuT.H. MohammedA.T. ElawadyS.S. GhoshP. ElgendyM.A. LeH.H. HamadW.M.A. IqtadarS. DumreS.P. HirayamaK. HuyN.T. The association between dengue viremia kinetics and dengue severity: A systemic review and meta-analysis.Rev. Med. Virol.202030611010.1002/rmv.212132856357
     [Google Scholar]
  56. GonçalvesA. BertrandJ. KeR. CometsE. de LamballerieX. MalvyD. PizzornoA. TerrierO. Rosa CalatravaM. MentréF. SmithP. PerelsonA.S. GuedjJ. Timing of antiviral treatment initiation is critical to Reduce SARS-CoV-2 viral load.CPT Pharmacometrics Syst. Pharmacol.20209950951410.1002/psp4.1254332558354
     [Google Scholar]
  57. DebsarmaD. SahaJ. GhoshS. Factors associated with delay in treatment-seeking behaviour for fever cases among caregivers of under-five children in India: Evidence from the national family health survey-4, 2015–16.PLoS One2022176e026984410.1371/journal.pone.026984435709164
     [Google Scholar]
  58. WatanabeS. ChanK.W.K. DowG. OoiE.E. LowJ.G. VasudevanS.G. Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: The search for a window for potential therapeutic efficacy.Antiviral Res.2016127101910.1016/j.antiviral.2015.12.00826794905
     [Google Scholar]
  59. VeitE.C. SalimM.S. JungM.J. RichardsonR.B. BoysI.N. QuinlanM. BarrallE.A. BednarskiE. HamiltonR.E. KikawaC. EldeN.C. García-SastreA. EvansM.J. Evolution of STAT2 resistance to flavivirus NS5 occurred multiple times despite genetic constraints.Nat. Commun.2024151542610.1038/s41467‑024‑49758‑038926343
     [Google Scholar]
  60. KaufmannB. RossmannM.G. Molecular mechanisms involved in the early steps of flavivirus cell entry.Microbes Infect.20111311910.1016/j.micinf.2010.09.00520869460
     [Google Scholar]
  61. StrasfeldL. ChouS. Antiviral drug resistance: Mechanisms and clinical implications.Infect. Dis. Clin. North Am.201024241343710.1016/j.idc.2010.01.00120466277
     [Google Scholar]
  62. ChenY.L. Abdul GhafarN. KarunaR. FuY. LimS.P. SchulW. GuF. HerveM. YokohamaF. WangG. CernyD. FinkK. BlascoF. ShiP.Y. Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir.J. Virol.20148831740174710.1128/JVI.02841‑1324257621
     [Google Scholar]
  63. ShyrZ.A. ChengY.S. LoD.C. ZhengW. Drug combination therapy for emerging viral diseases.Drug Discov. Today202126102367237610.1016/j.drudis.2021.05.00834023496
     [Google Scholar]
  64. DianiE. LagniA. LottiV. TononE. CecchettoR. GibelliniD. Vector-transmitted flaviviruses: An antiviral molecules overview.Microorganisms20231110242710.3390/microorganisms1110242737894085
     [Google Scholar]
  65. FibriansahG. IbarraK.D. NgT.S. SmithS.A. TanJ.L. LimX.N. OoiJ.S.G. KostyuchenkoV.A. WangJ. de SilvaA.M. HarrisE. CroweJ.E.Jr LokS.M. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers.Science20153496243889110.1126/science.aaa865126138979
     [Google Scholar]
  66. HarrisonS.C. Mechanism of membrane fusion by viral envelope proteins.Adv. Virus Res.20056423126110.1016/S0065‑3527(05)64007‑916139596
     [Google Scholar]
  67. RobinsonL.N. TharakaramanK. RowleyK.J. CostaV.V. ChanK.R. WongY.H. OngL.C. TanH.C. KochT. CainD. KirloskarR. ViswanathanK. LiewC.W. TissireH. RamakrishnanB. MyetteJ.R. BabcockG.J. SasisekharanV. AlonsoS. ChenJ. LescarJ. ShriverZ. OoiE.E. SasisekharanR. Structure-guided design of an anti-dengue antibody directed to a non-immunodominant epitope.Cell2015162349350410.1016/j.cell.2015.06.05726189681
     [Google Scholar]
  68. KhanM.B. YangZ.S. LinC.Y. HsuM.C. UrbinaA.N. AssavalapsakulW. WangW.H. ChenY.H. WangS.F. Dengue overview: An updated systemic review.J. Infect. Public Health202316101625164210.1016/j.jiph.2023.08.00137595484
     [Google Scholar]
  69. ZhaoC. ZhaoW. NLRP3 inflammasome—A key player in antiviral responses.Front. Immunol.20201121110.3389/fimmu.2020.0021132133002
     [Google Scholar]
  70. TanakaT. NarazakiM. KishimotoT. Immunotherapeutic implications of IL-6 blockade for cytokine storm.Immunotherapy20168895997010.2217/imt‑2016‑002027381687
     [Google Scholar]
  71. LiuT ZhangL JooD SunSC. NF NF-κB signaling in inflammation.Signal Transduct. Target. Ther.2017211910.1038/sigtrans.2017.2329158945
     [Google Scholar]
  72. UlmerJ.B. LiuM.A. Ethical issues for vaccines and immunization.Nat. Rev. Immunol.20022429129610.1038/nri78012002000
     [Google Scholar]
  73. SalischN.C. StephensonK.E. WilliamsK. CoxF. van der FitsL. HeerweghD. TruyersC. HabetsM.N. KanjilalD.G. LaroccaR.A. AbbinkP. LiuJ. PeterL. FierroC. De La BarreraR.A. ModjarradK. ZahnR.C. HendriksJ. CahillC.P. LeyssenM. DouoguihM. van HoofJ. SchuitemakerH. BarouchD.H. A double-blind, randomized, placebo-controlled phase 1 study of Ad26. ZIKV. 001, an Ad26-vectored anti–Zika virus vaccine.Ann. Intern. Med.2021174558559410.7326/M20‑530633587687
     [Google Scholar]
  74. DowdK.A. KoS.Y. MorabitoK.M. YangE.S. PelcR.S. DeMasoC.R. CastilhoL.R. AbbinkP. BoydM. NityanandamR. GordonD.N. GallagherJ.R. ChenX. ToddJ.P. TsybovskyY. HarrisA. HuangY.J.S. HiggsS. VanlandinghamD.L. AndersenH. LewisM.G. De La BarreraR. EckelsK.H. JarmanR.G. NasonM.C. BarouchD.H. RoedererM. KongW.P. MascolaJ.R. PiersonT.C. GrahamB.S. Rapid development of a DNA vaccine for Zika virus.Science2016354630923724010.1126/science.aai913727708058
     [Google Scholar]
  75. SabchareonA. WallaceD. SirivichayakulC. LimkittikulK. ChanthavanichP. SuvannadabbaS. JiwariyavejV. DulyachaiW. PengsaaK. WartelT.A. MoureauA. SavilleM. BouckenoogheA. VivianiS. TornieporthN.G. LangJ. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial.Lancet201238098531559156710.1016/S0140‑6736(12)61428‑722975340
     [Google Scholar]
  76. HalsteadS.B. Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age.Vaccine201735476355635810.1016/j.vaccine.2017.09.08929029938
     [Google Scholar]
  77. ThomasS.J. YoonI.K. A review of Dengvaxia®: Development to deployment.Hum. Vaccin. Immunother.201915102295231410.1080/21645515.2019.165850331589551
     [Google Scholar]
  78. PreciosoA.R. PalaciosR. ThoméB. MondiniG. BragaP. KalilJ. Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine.Vaccine201533507121712510.1016/j.vaccine.2015.09.10526458796
     [Google Scholar]
  79. KräutlerN.J. SuanD. ButtD. BourneK. HermesJ.R. ChanT.D. SundlingC. KaplanW. SchofieldP. JacksonJ. BastenA. ChristD. BrinkR. Differentiation of germinal center B cells into plasma cells is initiated by high-affinity antigen and completed by Tfh cells.J. Exp. Med.201721451259126710.1084/jem.2016153328363897
     [Google Scholar]
  80. LiuM. GanH. LiangZ. LiuL. LiuQ. MaiY. ChenH. LeiB. YuS. ChenH. ZhengP. SunB. Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies.Front. Microbiol.202314112286810.3389/fmicb.2023.112286837007494
     [Google Scholar]
  81. UhuamiA.O. LawalN. BelloM.B. ImamM.U. Flavivirus cross-reactivity: Insights into e-protein conservancy, pre-existing immunity, and co-infection.Microbe2024410010510.1016/j.microb.2024.100105
     [Google Scholar]
  82. CollinsM.H. McGowanE. JadiR. YoungE. LopezC.A. BaricR.S. LazearH.M. de SilvaA.M. Lack of durable cross-neutralizing antibodies against Zika virus from dengue virus infection.Emerg. Infect. Dis.201723577378110.3201/eid2305.16163028418292
     [Google Scholar]
  83. MontoyaM. CollinsM. DejnirattisaiW. KatzelnickL.C. Puerta-GuardoH. JadiR. SchildhauerS. SupasaP. VasanawathanaS. MalasitP. MongkolsapayaJ. de SilvaA.D. TisseraH. BalmasedaA. ScreatonG. de SilvaA.M. HarrisE. Longitudinal analysis of antibody cross-neutralization following Zika virus and dengue virus infection in Asia and the Americas.J. Infect. Dis.2018218453654510.1093/infdis/jiy16429618091
     [Google Scholar]
  84. MansuyJ.M. SuberbielleE. Chapuy-RegaudS. MengelleC. BujanL. MarchouB. DelobelP. Gonzalez-DuniaD. MalnouC.E. IzopetJ. Martin-BlondelG. Zika virus in semen and spermatozoa.Lancet Infect. Dis.201616101106110710.1016/S1473‑3099(16)30336‑X27676340
     [Google Scholar]
  85. LindseyN.P. StaplesJ.E. PowellK. RabeI.B. FischerM. PowersA.M. KosoyO.I. MosselE.C. Munoz-JordanJ.L. BeltranM. HancockW.T. ToewsK.E. EllisE.M. EllisB.R. PanellaA.J. BasileA.J. CalvertA.E. LavenJ. GoodmanC.H. GouldC.V. MartinS.W. ThomasJ.D. VillanuevaJ. MataiaM.L. SciulliR. GoseR. WhelenA.C. HillsS.L. Ability to serologically confirm recent Zika virus infection in areas with varying past incidence of dengue virus infection in the United States and US territories in 2016.J. Clin. Microbiol.20175611012829093104
     [Google Scholar]
  86. ScreatonG. MongkolsapayaJ. YacoubS. RobertsC. New insights into the immunopathology and control of dengue virus infection.Nat. Rev. Immunol.2015151274575910.1038/nri391626603900
     [Google Scholar]
  87. StettlerK. BeltramelloM. EspinosaD.A. GrahamV. CassottaA. BianchiS. VanzettaF. MinolaA. JaconiS. MeleF. FoglieriniM. PedottiM. SimonelliL. DowallS. AtkinsonB. PercivalleE. SimmonsC.P. VaraniL. BlumJ. BaldantiF. CameroniE. HewsonR. HarrisE. LanzavecchiaA. SallustoF. CortiD. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection.Science2016353630182382610.1126/science.aaf850527417494
     [Google Scholar]
  88. HuT. WuZ. WuS. ChenS. ChengA. The key amino acids of E protein involved in early flavivirus infection: viral entry.Virol. J.202118113610.1186/s12985‑021‑01611‑234217298
     [Google Scholar]
  89. KuhnR.J. BarrettA.D.T. DesilvaA.M. HarrisE. KramerL.D. MontgomeryR.R. PiersonT.C. SetteA. DiamondM.S. A prototype-pathogen approach for the development of flavivirus countermeasures.J. Infect. Dis.2023228Suppl. 6S398S41310.1093/infdis/jiad19337849402
     [Google Scholar]
/content/journals/cbiot/10.2174/0122115501364702250707105742
Loading

  • Article Type:     Review Article
Keyword(s): Antibody-dependent enhancement; Fc receptor; flaviviruses; neutralising antibody; therapeutics; vaccine development

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test